Merck's Keytruda Enjoys Clean Sweep In Lung Cancer, At Bristol's Expense

 
• By Emily Hayes

Merck came out ahead in the immuno-oncology combination showdown at AACR, with a strong overall survival benefit for Keytruda/chemo in the Phase III KEYNOTE-189 study in first-line NSCLC. The data were seen as practice-changing, but Bristol's CheckMate-227 trial of Opdivo/Yervoy failed to impress in the same way.

Instagram style filter silhouette of a successful woman or girl arms raised celebrating at sunrise or sunset in front of the New York City Skyline

More from Immuno-oncology

More from Anticancer